Introduction to Vizimpro (Dacomitinib) 45mg 

Vizimpro (Dacomitinib) 45mg is a prescription medicine used for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This targeted therapy belongs to a class of oncology drugs that block abnormal signaling pathways responsible for cancer cell growth and survival.

Vizimpro (Dacomitinib) 45mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapies, and Oral Anticancer Drugs. It contains Dacomitinib, which works by irreversibly inhibiting epidermal growth factor receptor (EGFR) tyrosine kinases, helping to slow tumor progression and reduce cancer cell proliferation.

In some markets, Deconib 45mg is available as a generic brand containing the same active ingredient Dacomitinib, offering a similar therapeutic effect when prescribed by a qualified healthcare professional.

What Is Vizimpro (Dacomitinib)? 

Vizimpro is the brand name for Dacomitinib, an oral medication widely used for the treatment of EGFR mutation-positive advanced non-small cell lung cancer.

Dacomitinib belongs to a class of medicines known as EGFR Tyrosine Kinase Inhibitors (TKIs). These medicines work by blocking specific signaling pathways that cancer cells use to grow and survive.

Generic versions such as Deconib 45mg contain the same active compound and may be used depending on physician recommendation and regional availability.

Drug Class and Mechanism of Action 

Dacomitinib is classified as a targeted anticancer therapy and EGFR tyrosine kinase inhibitor with antineoplastic properties.

How Dacomitinib Works 

It works in several ways:

• Irreversibly inhibits EGFR tyrosine kinase activity
• Blocks cancer cell growth and survival signals
• Promotes apoptosis (programmed cell death) in cancer cells

Through these mechanisms, Dacomitinib helps slow or stop the progression of EGFR-positive non-small cell lung cancer.

How Vizimpro Works in the Body 

Cancer cells in EGFR-positive NSCLC rely on abnormal EGFR signaling for growth and survival. Vizimpro blocks these pathways, reducing tumor progression and helping control the disease.

Key Actions of Dacomitinib 

• Inhibits EGFR signaling in cancer cells
• Reduces cancer cell proliferation
• Promotes cancer cell apoptosis

Some generic versions such as Deconib deliver the same active compound, allowing similar targeted therapy when prescribed appropriately.

Medical Uses of Vizimpro (Dacomitinib) 45mg 

Vizimpro 45mg is prescribed for patients with specific EGFR mutation-positive non-small cell lung cancers.

Vizimpro for Non-Small Cell Lung Cancer (NSCLC) 

Vizimpro is used as a first-line treatment in patients with advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitutions.

Potential Benefits 

• Targets EGFR-driven tumors
• Slows disease progression
• Provides an alternative to traditional chemotherapy

Generic alternatives like Deconib 45mg may also be used under medical supervision when Dacomitinib therapy is recommended.

Who Can Take Deconib 45mg? 

Because Dacomitinib is a potent targeted therapy, treatment should always be supervised by an experienced oncologist.

Eligibility Criteria 

Patients may be prescribed Vizimpro if they:

• Have EGFR mutation-positive advanced or metastatic NSCLC
• Require first-line targeted therapy
• Are suitable candidates for oral EGFR tyrosine kinase inhibitors

Certain generic options such as Deconib may also be considered depending on availability and physician decision.

Who Should Avoid Vizimpro (Dacomitinib) 45mg 

Vizimpro should NOT be used by:

• Individuals with hypersensitivity to Dacomitinib
• Patients with severe liver impairment unless monitored
• Individuals with significant cardiovascular disease or interstitial lung disease without specialist supervision

Vizimpro (Dacomitinib) 45mg Dosage and Administration 

Standard Dosage Guidelines 

Typical dosage recommendations include:

• Vizimpro 45mg taken once daily
• Capsules should be swallowed whole with water
• Can be taken with or without food

Dosage Adjustments 

Doctors may adjust the dose depending on:

• Liver function tests
• Side effects such as diarrhea or skin rash
• Individual treatment response

Side Effects of Vizimpro 45mg 

Like many targeted cancer medicines, Vizimpro may cause side effects.

Common Side Effects 

• Diarrhea
• Skin rash or acne-like eruptions
• Mouth sores
• Fatigue

Serious Side Effects 

• Liver toxicity
• Interstitial lung disease (ILD)
• Heart rhythm abnormalities (QT prolongation)

Patients should report any unusual symptoms to their doctor immediately.

Storage:
Store below 25°C in a cool, dry place, protected from moisture and direct sunlight. Keep the capsules in their original packaging and out of reach of children.

Frequently Asked Questions (FAQs) 

1. What type of cancer is Vizimpro (Dacomitinib) 45mg used for? 

Vizimpro is mainly used to treat advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.

2. Is Vizimpro chemotherapy? 

No. Vizimpro is not traditional chemotherapy. It is a targeted therapy that inhibits EGFR tyrosine kinase in cancer cells.

3. Do patients need genetic testing before taking Dacomitinib? 

Yes. Patients must undergo EGFR mutation testing to confirm eligibility for Dacomitinib treatment.

4. Can Deconib 45mg be taken with food? 

Yes. Dacomitinib capsules can generally be taken with or without food unless directed otherwise by a doctor.

5. Can pregnant women take Deconib 45mg? 

No. Deconib 45mg should not be used during pregnancy as Dacomitinib may harm an unborn baby.

6. Is Deconib 45mg the same as Vizimpro? 

Deconib 45mg contains Dacomitinib, the same active ingredient found in Vizimpro. Generic versions is available. for more info. contact on WhatsApp: https://wa.me/8801742433764

7. Do I need a prescription to buy Deconib (Dacomitinib) 45mg? 

Yes. Deconib 45mg is a prescription-only medicine and should only be used under the supervision of a qualified healthcare professional.

Medical Disclaimer 

Disclaimer:
The information provided on this page is for educational and informational purposes only and should not be considered medical advice. Vizimpro (Dacomitinib) is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. Always consult your physician before starting, stopping, or changing any medication.